Last updated: September 15, 2026
Homatropine methylbromide and hydrocodone bitartrate is a legacy opioid antitussive combination sold in tablet and oral-solution formats under brand and generic names including Hycodan and related products. Its commercial outlook is mature to declining. The product has no meaningful remaining small-molecule patent exclusivity, faces extensive opioid regulation, and competes with lower-risk nonopioid cough medicines. Revenue is likely concentrated among a limited number of manufacturers and distributors, with financial performance driven more by supply availability, controlled-substance quotas, manufacturing compliance and generic competition than by prescription growth.
What is homatropine methylbromide and hydrocodone bitartrate used for?
The combination is indicated for symptomatic relief of cough. Hydrocodone provides the antitussive activity, while homatropine methylbromide is included in a quantity intended to discourage excessive use of the formulation. The product is available in oral tablets and oral solutions, with strengths varying by manufacturer and product presentation.
Hydrocodone is a semisynthetic opioid and a Schedule II controlled substance in the United States. The combination carries opioid-class warnings for respiratory depression, misuse, abuse, addiction, overdose and death. Alcohol, benzodiazepines and other central nervous system depressants increase the risk of serious adverse events. [1]
The product is distinct from hydrocodone-acetaminophen analgesics such as Norco and Vicodin. It contains no acetaminophen and is marketed primarily for cough suppression rather than pain management.
What is the FDA regulatory status of hydrocodone-homatropine?
The combination is an FDA-approved prescription cough medicine, but its regulatory environment has tightened significantly since the original products entered the market.
| Regulatory factor |
Commercial effect |
| Hydrocodone Schedule II status |
Requires controlled-substance registration, security controls, recordkeeping and quota allocation |
| Prescription-only status |
Limits consumer access and increases prescriber scrutiny |
| Opioid labeling requirements |
Raises compliance and pharmacovigilance costs |
| Pediatric restrictions |
Reduces addressable demand in children and adolescents |
| State opioid rules |
Creates variable dispensing, prescribing and documentation requirements |
| FDA manufacturing requirements |
Increases supply-chain and quality-system costs |
| Abuse-deterrence and misuse concerns |
Favors nonopioid competitors in some prescribing settings |
In 2018, the FDA required labeling changes for prescription cough and cold medicines containing codeine or hydrocodone. These products are not approved for use in children younger than 18 because of the risk of misuse, addiction, overdose and respiratory depression. [2]
Hydrocodone combination products were moved from Schedule III to Schedule II in 2014. The change eliminated refills and required a new prescription for each dispensing, adding friction to repeat use. [3]
What patents protect homatropine methylbromide and hydrocodone bitartrate?
The core combination is a legacy product and does not have a commercially meaningful remaining composition-of-matter patent estate in the United States.
| IP category |
Current commercial relevance |
| Hydrocodone bitartrate active ingredient |
No meaningful remaining primary patent protection |
| Homatropine methylbromide active ingredient |
No meaningful remaining primary patent protection |
| Basic hydrocodone-homatropine combination |
Legacy technology; likely long expired |
| Standard tablets |
Generally vulnerable to generic competition |
| Standard oral solutions |
Generally vulnerable to generic competition |
| Method-of-use patents |
No material exclusivity expected for the basic cough indication |
| Manufacturing patents |
Possible process know-how, but limited blocking value |
| Formulation patents |
Potentially relevant only to differentiated delivery systems or excipients |
| Biosimilar protection |
Not applicable; this is a small-molecule drug |
The commercial barrier is therefore not the basic patent estate. It is the ability to manufacture, source and distribute a Schedule II opioid in compliance with FDA and Drug Enforcement Administration requirements.
The Orange Book remains relevant for identifying approved applications, reference-listed drugs and any listed patents or exclusivity statements. For a legacy product such as hydrocodone-homatropine, the practical expectation is that any original patent protection has expired and that approved generic products can compete without a patent-based launch restriction. [4]
When does hydrocodone-homatropine lose exclusivity?
The product lost meaningful market exclusivity decades ago. Exact protection dates depend on the original application, dosage form and any historical regulatory extensions, but the combination predates the modern Hatch-Waxman period by many years.
No current revenue thesis should rely on:
- New chemical entity exclusivity
- Orphan-drug exclusivity
- Pediatric exclusivity
- A live composition-of-matter patent
- A current formulation patent covering ordinary tablets or oral solution
- A meaningful method-of-use patent blocking generic cough treatment
The absence of current exclusivity allows multiple manufacturers to market equivalent products. Generic approval under an abbreviated new drug application generally does not require a new clinical efficacy program when the product meets applicable equivalence and labeling requirements.
How many patents cover hydrocodone bitartrate and homatropine methylbromide?
The core product is unlikely to have an active blocking patent portfolio of commercial significance. Patent-count analysis should distinguish between historical patents, expired patents, abandoned applications and active patents listed for a specific approved product.
A high patent count would not necessarily indicate meaningful protection because:
- Many records may relate to expired legacy products.
- A patent may cover a narrow process rather than the commercial product.
- Unlisted patents may not prevent ANDA approval.
- Manufacturing know-how may be difficult to replicate without creating a legal barrier.
- A generic competitor can often design around a narrow formulation claim.
The relevant IP risk is therefore low for the basic combination. A manufacturer with a novel abuse-deterrent formulation, modified-release dosage form or proprietary delivery technology could create a separate patent position, but that would represent a differentiated product rather than ordinary hydrocodone-homatropine.
What is the Orange Book status of hydrocodone-homatropine?
The FDA Orange Book is the controlling reference for approved products, reference-listed drugs, therapeutic-equivalence codes and listed patents. Brand and generic entries can differ by dosage form, strength, applicant and approval pathway.
For commercial diligence, the relevant questions are:
- Which product is the reference-listed drug?
- Which tablets and oral solutions have therapeutic-equivalence designations?
- Are any patents listed against a current application?
- Are there unexpired exclusivity periods?
- Do products have different strengths or inactive ingredients?
- Are all listed presentations commercially available?
A generic product can face practical substitution limits even where the product is therapeutically equivalent. Pharmacies may encounter differences in package size, wholesaler inventory, state scheduling procedures, or payer formulary treatment.
Which companies compete in the hydrocodone-homatropine market?
Competition comes from generic manufacturers and from alternative cough products rather than from a single dominant branded franchise.
Direct generic competitors
Direct competition may include manufacturers marketing hydrocodone bitartrate and homatropine methylbromide tablets or oral solutions under their own labels. Availability changes over time because controlled-substance quotas, production decisions and wholesaler purchasing can remove products from the market without a formal regulatory withdrawal.
Therapeutic competitors
The main alternatives include:
- Dextromethorphan products
- Benzonatate
- Codeine-containing cough products
- Promethazine with dextromethorphan
- Guaifenesin combinations
- Nonprescription cough and cold products
- Treatment of the underlying condition rather than suppression of cough
Hydrocodone products generally carry a higher regulatory and prescribing burden than dextromethorphan or benzonatate. This makes substitution likely when clinical circumstances do not require an opioid antitussive.
What formulations are protected by hydrocodone-homatropine patents?
Standard immediate-release tablets and oral solutions have limited patent-based differentiation. The strongest potential protection would apply to a formulation that materially changes the product’s technical or commercial profile, such as:
- Abuse-deterrent technology
- Modified or extended release
- A novel liquid delivery system
- Improved chemical stability
- Tamper-resistant packaging tied to a product claim
- A formulation that reduces dosing frequency
- A combination with a separately protected active ingredient
No such differentiated formulation should be assumed to have market significance without a current patent, approved label and evidence of commercial distribution. Ordinary generic tablets and syrups remain exposed to substitution.
What patent litigation affects hydrocodone-homatropine?
The product does not present the type of active patent litigation associated with newer specialty pharmaceuticals. The central legal risks are regulatory and commercial:
- Controlled-substance compliance
- DEA quota allocation
- FDA manufacturing inspections
- Product-quality investigations
- Opioid marketing and distribution litigation
- State enforcement actions
- Product-liability claims
- Supply-chain and diversion controls
A Paragraph IV challenge is unlikely to be a major current market event for the basic product because the principal exclusivity period has expired. Generic applicants may still file certifications where a listed patent exists, but the commercial impact would depend on the patent’s status, scope and expiration date.
There is no biosimilar pathway because hydrocodone-homatropine is a chemically synthesized small-molecule product. Biosimilar competition is therefore irrelevant. The applicable competitive mechanism is generic substitution under the Hatch-Waxman framework.
What generic entry risks exist for the branded product?
Generic entry risk is effectively structural rather than event-driven. The product is already exposed to generic competition.
| Risk |
Assessment |
| New tablet generic entry |
High, subject to supply economics and regulatory approval |
| New oral-solution generic entry |
High, but manufacturing and packaging may be more complex |
| Price erosion |
Moderate to high |
| Complete displacement of brand |
Possible in payer channels |
| Supply shortages |
Material countervailing factor |
| Prescription growth |
Low |
| Opioid regulatory tightening |
High |
| Product discontinuation |
Possible if margins fall below compliance and manufacturing costs |
The market can remain commercially viable despite weak patent protection if a small number of manufacturers exit. This creates a market in which generic prices may rise temporarily during shortages even though long-term pricing pressure remains negative.
How strong is the patent estate for hydrocodone-homatropine?
The patent estate is weak for the base product and does not support premium valuation based on exclusivity.
A practical scorecard is:
| Patent-estate factor |
Assessment |
| Composition-of-matter protection |
None of current commercial significance |
| Formulation protection |
Limited for ordinary products |
| Method-of-use protection |
Limited |
| Manufacturing protection |
Possible but unlikely to block generic entry |
| Patent litigation leverage |
Low |
| Exclusivity duration |
Fully mature |
| Generic vulnerability |
High |
| Regulatory barrier |
Moderate to high |
| Supply-chain barrier |
Moderate |
| Commercial differentiation |
Low |
The strongest defensible assets are operational: controlled-substance licenses, reliable API sourcing, validated manufacturing capacity, compliant distribution and established pharmacy relationships.
What is the financial trajectory for hydrocodone-homatropine?
The financial trajectory is mature, fragmented and likely declining in volume, with episodic pricing strength caused by shortages.
Revenue drivers
Revenue is influenced by:
- Number of active generic suppliers
- DEA production quotas
- Hydrocodone API availability
- FDA inspection outcomes
- Prescriber willingness to use opioid antitussives
- Pediatric prescribing restrictions
- State opioid regulations
- Payer substitution
- Wholesale acquisition pricing
- Discontinuation of competing products
Margin profile
Manufacturing margins can be higher than those of ordinary generic tablets because of controlled-substance compliance, security, testing, inventory controls and quota management. Those costs also limit the number of viable suppliers.
An established manufacturer may achieve attractive short-term revenue during a shortage. The same manufacturer faces weak long-term pricing power because the product is therapeutically mature and lacks patent protection.
Revenue exposure
Public companies generally do not disclose hydrocodone-homatropine revenue as a separate line item. The product is usually aggregated within generic pharmaceuticals or prescription products. As a result, brand-level sales, market share and gross-margin estimates require prescription audits or proprietary commercial databases.
The financial profile can be summarized as follows:
| Period |
Expected market characteristic |
| Historical period |
Brand-led sales followed by generic erosion |
| Current mature period |
Low-growth or declining demand with supplier volatility |
| Short term |
Potential price and revenue spikes during shortages |
| Medium term |
Continued substitution and regulatory pressure |
| Long term |
Niche availability, possible supplier consolidation or discontinuation |
What manufacturing and IP barriers affect the product?
The main barriers are operational rather than patent-based.
Controlled hydrocodone API
Hydrocodone is subject to federal production controls. Manufacturers must operate within quota and registration frameworks administered by the DEA. API suppliers also face security, diversion and recordkeeping requirements.
Oral-solution manufacturing
Liquid products can require more complex controls involving:
- Homogeneous distribution of the active ingredient
- Stability over shelf life
- Accurate dosing devices
- Child-resistant packaging
- Microbiological control
- Tamper-evident packaging
- Serialization and distribution tracking
These requirements can discourage entry even when no patent blocks approval.
Distribution controls
Wholesalers and pharmacies apply controlled-substance monitoring rules and may impose purchasing limits. Manufacturers with established compliance systems have an advantage over new entrants.
How does hydrocodone-homatropine compare with other prescription cough medicines?
| Product |
Opioid risk |
Patent position |
Prescription demand outlook |
Main commercial advantage |
| Hydrocodone-homatropine |
High |
Mature, weak |
Declining or niche |
Potent antitussive effect |
| Codeine cough products |
High |
Mature, weak |
Declining |
Low-cost legacy use |
| Dextromethorphan |
Lower than opioids |
Mature |
Broad |
OTC access and lower regulatory burden |
| Benzonatate |
Nonopioid but prescription |
Mature |
Stable niche |
Avoids opioid scheduling |
| Promethazine-DM |
Lower opioid exposure |
Mature |
Competitive |
Combination symptom relief |
| Guaifenesin products |
Nonopioid |
Mature |
Broad |
Expectorant positioning |
Hydrocodone-homatropine retains a niche where prescribers seek an opioid antitussive, but its addressable market is narrower than it was before opioid safety restrictions intensified.
What generic launch scenarios are most likely?
The most likely scenarios are:
- Stable generic supply with gradual volume decline. Multiple suppliers remain active, pricing stays competitive and opioid prescribing continues to contract.
- Supplier consolidation. Low volume and compliance costs cause manufacturers to exit, leaving fewer suppliers.
- Shortage-driven price expansion. A quota reduction, API disruption or manufacturing problem causes temporary pricing power.
- Brand retreat. A branded product loses formulary access and becomes commercially marginal.
- Niche persistence. The product remains available because some clinicians and patients continue to require an opioid antitussive despite declining use.
The least likely scenario is a patent-driven exclusivity recovery for the legacy formulation.
Key Takeaways
- Homatropine methylbromide and hydrocodone bitartrate is a mature opioid cough product with no meaningful remaining core patent protection.
- The product is regulated as a hydrocodone-containing Schedule II medicine.
- FDA pediatric restrictions and opioid-labeling requirements limit demand.
- Generic competition is established, while new Paragraph IV litigation is unlikely to reshape the market.
- Biosimilar risk does not apply because the product is a small molecule.
- Financial performance depends on quota access, API sourcing, manufacturing compliance and supplier exits.
- Short-term revenue can improve during shortages, but long-term volume and pricing remain under pressure.
- The strongest commercial assets are manufacturing and distribution capabilities, not intellectual property.
FAQs
Is hydrocodone-homatropine still commercially available?
Availability varies by manufacturer, dosage form, wholesaler inventory and DEA quota conditions. Generic tablets and oral solutions may not be continuously available from every supplier.
Is Hycodan protected by an active patent?
The legacy hydrocodone-homatropine formulation is not generally viewed as having commercially meaningful active core patent protection. Current product-specific Orange Book records control any remaining listed protection.
Can a generic manufacturer launch hydrocodone-homatropine without a Paragraph IV challenge?
Yes. If no unexpired blocking patent or exclusivity period applies to the relevant reference product, an ANDA applicant does not need to rely on a Paragraph IV certification to enter.
Does hydrocodone-homatropine have abuse-deterrent labeling?
Standard hydrocodone-homatropine tablets and oral solutions should not be treated as abuse-deterrent products unless the FDA-approved labeling expressly identifies abuse-deterrent properties.
Is hydrocodone-homatropine a growth product for generic pharmaceutical companies?
It is generally a mature niche product rather than a growth asset. It can contribute attractive episodic revenue during shortages, but its long-term outlook is constrained by opioid regulation, declining utilization and generic competition.
References
- U.S. Food and Drug Administration. (n.d.). Hydrocodone bitartrate and homatropine methylbromide prescribing information. DailyMed.
- U.S. Food and Drug Administration. (2018, January 11). FDA requires labeling changes for prescription opioid cough and cold medicines to limit their use to adults 18 years and older.
- U.S. Drug Enforcement Administration. (2014, August 22). Schedules of controlled substances: Rescheduling of hydrocodone combination products from Schedule III to Schedule II. 79 Fed. Reg. 49661.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.
